年轻女性激素受体阳性早期乳腺癌：全面综述。
Hormone receptor-positive early breast cancer in young women: A comprehensive review.
发表日期：2024 Jul 14
作者：
Benjamin Walbaum, Isabel García-Fructuoso, Olga Martínez-Sáez, Francesco Schettini, César Sánchez, Francisco Acevedo, Nuria Chic, Javier Muñoz-Carrillo, Barbara Adamo, Montserrat Muñoz, Ann H Partridge, Meritxell Bellet, Fara Brasó-Maristany, Aleix Prat, Maria Vidal
来源：
CANCER TREATMENT REVIEWS
摘要：
近几十年来，≤ 40 岁女性 (YWBC) 的乳腺癌发病率一直在稳步上升。尽管这组患者仅占所有新诊断 BC 病例的不到 10%，但其疾病负担却相当沉重。 YWBC 通常在临床试验中代表性不足，其特点还在于诊断较晚、分化差、侵袭性亚型疾病，部分解释了其预后不良以及高复发风险和高死亡率。另一方面，YWBC 治疗提出了独特的挑战，例如保留生育能力、长期毒性和不良事件。在此，我们总结了激素受体阳性 YWBC 的当前证据，包括特定危险因素、临床病理学和基因组特征，以及化疗和内分泌治疗反应的现有证据。总体而言，我们主张采用更全面的多学科医疗保健模式，以改善这部分年轻患者的治疗结果和生活质量。版权所有 © 2024 Elsevier Ltd。保留所有权利。
The incidence of breast cancer in ≤ 40 yr-old women (YWBC) has been steadily increasing in recent decades. Although this group of patients represents less than 10 % of all newly diagnosed BC cases it encompasses a significant burden of disease. Usually underrepresented in clinical trials, YWBCs are also characterized by late diagnoses and poorly differentiated, aggressive-subtype disease, partly explaining its poor prognosis along with a high recurrence risk, and high mortality rates. On the other hand, YWBC treatment poses unique challenges such as preservation of fertility, and long-term toxicity and adverse events. Herein, we summarize the current evidence in hormone receptor-positive YWBC including specific risk factors, clinicopathologic and genomic features, and available evidence on response to chemotherapy and endocrine therapy. Overall, we advocate for a more comprehensive multidisciplinary healthcare model to improve the outcomes and the quality of life of this subset of younger patients.Copyright © 2024 Elsevier Ltd. All rights reserved.